Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Investor conferences sits at the center of this dementia and brain health question.
Major pharmaceutical and biotech companies are actively presenting Alzheimer’s treatment research and clinical trial data at leading investor conferences around the world. These presentations have become critical events for both the scientific community and investment markets, as companies showcase their latest drug candidates, real-world evidence, and pathway to regulatory approval. In 2026 alone, three major conferences dedicated to neurodegeneration and Alzheimer’s disease will draw researchers, clinicians, and investors eager to learn about breakthrough treatments that could transform how we approach dementia care.
The presentations span a range of therapeutic approaches—from monoclonal antibodies targeting amyloid protein to novel anti-inflammatory compounds—and are attracting significant institutional attention. For example, Biogen’s presentation of lecanemab data at the 2025 Alzheimer’s Association International Conference (AAIC), including 48-month results and real-world treatment evidence, demonstrated how investor conferences have become venues where companies validate the long-term safety and efficacy of treatments already entering the market. These investor conferences serve a dual purpose: they advance scientific understanding of Alzheimer’s disease mechanisms while simultaneously signaling to capital markets which companies are making genuine progress in drug development. Understanding what these conferences feature helps patients, families, and caregivers stay informed about emerging treatment options that may eventually become available.
Table of Contents
- What Are the Major Alzheimer’s Conferences Attracting Investor Presentations?
- Which Alzheimer’s Treatment Companies Are Presenting at These Conferences?
- What Types of Data Do Companies Present at These Conferences?
- How Do These Presentations Influence Investment in Alzheimer’s Research?
- What Clinical Trial Advancements Are Showcased at These Forums?
- How Do Real-World Evidence and Emerging Therapies Feature in Conference Presentations?
- What Does the Future Hold for Alzheimer’s Treatment Presentations at Investor Conferences?
- Conclusion
What Are the Major Alzheimer’s Conferences Attracting Investor Presentations?
Several premier conferences have established themselves as must-attend events for Alzheimer’s treatment companies. The Alzheimer’s Association International Conference (AAIC) stands out as the world’s largest international conference dedicated to dementia science and clinical practice, with the 2026 edition scheduled for July 12-15 in London, United Kingdom. The AD/PD Conference represents another significant venue, drawing over 5,500 participants from more than 70 countries and receiving more than 2,500 abstracts—making it the leading event in neurodegenerative disorders research. Specialized investment-focused conferences also feature Alzheimer’s treatment presentations.
The Alzheimer Society International Congress (ASIC) will take place May 18-20, 2026, in San Francisco, with a specific focus on investment opportunities across Alzheimer’s therapeutics, devices, biotech, and healthcare services. Similarly, the Clinical Trials on Alzheimer’s Disease conference (CTAD) is scheduled for November 16-19, 2026, in Boston, Massachusetts, providing another critical platform for companies to present trial data and engage with researchers and investors. The sheer scale of these events underscores their importance: AAIC draws thousands of attendees globally, ASIC provides direct investor connections in the financial technology hub of San Francisco, and CTAD offers a specialized focus on trial design and clinical advancement. This variety ensures that companies can reach different audience segments throughout the calendar year.
Which Alzheimer’s Treatment Companies Are Presenting at These Conferences?
Leading pharmaceutical giants and specialized biotech firms are competing for attention at major Alzheimer’s conferences. Biogen has become a fixture at AAIC, presenting data on lecanemab—a treatment already approved by the FDA that targets amyloid in the brain. At the 2025 AAIC conference held in Toronto, Biogen presented 48-month results from the Clarity AD open-label extension study, real-world treatment evidence showing how lecanemab performs outside of controlled trials, and data on a subcutaneous formulation that would allow patients to inject the drug themselves rather than receive intravenous infusions in clinical settings. Roche has similarly leveraged investor conferences to advance its pipeline. At the 2025 AAIC conference, Roche presented Phase Ib/IIa results from the Brainshuttle™ AD study and detailed the Phase III trial designs for trontinemab—a drug candidate the company is developing to address Alzheimer’s disease through a different mechanism than amyloid-targeting antibodies.
GlaxoSmithKline (GSK) presented six abstracts at AAIC 2025 detailing inflammation and immunology research approaches to treating neurodegenerative diseases, reflecting a growing recognition that Alzheimer’s may involve multiple biological pathways requiring different therapeutic strategies. Smaller biotech companies also use investor conferences as platforms for visibility. Anavex Life Sciences presented ATTENTION-AD Open-Label-Extension trial data at the J.P. Morgan 2025 Healthcare Conference in January, demonstrating that investor conferences aren’t limited to research-focused events—major healthcare investment conferences also feature Alzheimer’s treatments. This diversity of companies and approaches means that the field is not dependent on any single breakthrough, reducing risk for patients hoping for new treatment options.
What Types of Data Do Companies Present at These Conferences?
Alzheimer’s treatment companies present multiple categories of clinical and real-world evidence at investor conferences. Long-term safety and efficacy data dominates presentations: Biogen’s 48-month follow-up results from lecanemab trials, for instance, address a critical investor and patient concern—do the cognitive benefits of early Alzheimer’s treatment persist over time, or does disease progression eventually catch up? Multi-year data helps answer this question and demonstrates that a company’s treatment has staying power. Real-world evidence has become increasingly important in recent years. Rather than relying solely on controlled clinical trials where patients receive structured care and careful monitoring, companies now present data showing how treatments perform when used in actual clinical practice.
This type of evidence helps answer practical questions: Do patients tolerate the treatment when given by their regular neurologist rather than a trial coordinator? Do they complete the full course of treatment, or do side effects or inconvenience lead to discontinuation? How does cognitive decline slow down in everyday practice compared to controlled trial settings? A limitation of real-world data is that it cannot establish causality with the same certainty as randomized trials, but it provides crucial information about practical effectiveness. Companies also present mechanistic data and trial design details, as Roche did with its Brainshuttle™ and trontinemab presentations. These presentations help investors understand not just whether a drug works, but why it works and which biological processes it targets. This information is particularly valuable when multiple companies are pursuing different approaches to Alzheimer’s treatment, as it helps investors and patients understand how the company’s strategy differs from competitors.
How Do These Presentations Influence Investment in Alzheimer’s Research?
Investor conferences are critical milestones that can dramatically affect capital flow into Alzheimer’s drug development. A positive data presentation can validate a company’s research direction, reduce perceived risk, and lead to stock price appreciation or increased institutional investment. Conversely, disappointing trial results presented at these forums can trigger sharp sell-offs. This means that the timing and venue of data presentation matters enormously—companies carefully plan when and where to unveil results to maximize impact on both the scientific and investment communities.
The presence of major pharmaceutical companies like Roche, GSK, and Biogen at these conferences signals that Alzheimer’s disease is now considered a major market opportunity. This attracts smaller biotech companies seeking partnerships or acquisition opportunities and encourages venture capital investment in early-stage companies with novel approaches. However, there is a tradeoff: as Alzheimer’s research becomes more lucrative, companies may be incentivized to pursue profitable drugs targeting wealthy Western markets rather than addressing neurodegeneration in lower-income countries or earlier stages of cognitive decline that may affect younger adults. The concentration of presentations by large companies can also create a perception that only expensive, complex treatments are viable—potentially overshadowing research into prevention, lifestyle interventions, or treatments targeting earlier disease stages. Smaller specialized conferences like those focused on specific mechanisms of neurodegeneration may receive less attention and funding despite potentially offering complementary approaches.
What Clinical Trial Advancements Are Showcased at These Forums?
Major Alzheimer’s conferences highlight how clinical trial design has evolved to address practical and scientific challenges. Roche’s presentation of Phase III trial designs for trontinemab at AAIC, for example, demonstrates how companies are learning from earlier Alzheimer’s trials and building in features like extended follow-up periods and real-world implementation strategies. Phase III trials represent the final stage before regulatory approval and typically enroll thousands of patients across multiple countries—these presentations show investors and the scientific community what evidence will ultimately support FDA or EMA approval. Long-term extension studies, like the Clarity AD open-label extension study from which Biogen pulled its 48-month data, have become standard in Alzheimer’s research. These extensions address a critical limitation: traditional trial periods typically last 18 months to 2 years, but Alzheimer’s disease progresses over decades.
Open-label extensions allow patients who completed the initial trial to continue receiving active treatment, and researchers can track outcomes over much longer periods. A limitation of these studies is that they lack a placebo control group—researchers cannot determine whether the long-term cognitive stability reflects the treatment’s benefit or simply represents natural variation in disease progression rates among patients who chose to continue in the study. Companies are also presenting data on alternative delivery methods, such as Biogen’s subcutaneous formulation of lecanemab. This addresses a practical barrier to treatment: intravenous infusions require regular clinic visits, which can be burdensome for elderly patients with cognitive decline. A warning about newer formulations is that they are often still in development, and side effects or efficacy may differ from the original intravenous version—patient preferences for convenience must be balanced against rigorous testing of new delivery approaches.
How Do Real-World Evidence and Emerging Therapies Feature in Conference Presentations?
Real-world evidence presentations have become centerpieces of investor conferences, particularly as regulators increasingly expect companies to demonstrate that approved drugs actually help patients in everyday clinical practice. Biogen’s presentation of real-world treatment evidence for lecanemab showed how the drug performs when administered by community neurologists and memory specialists outside the controlled trial setting. This evidence matters because trial patients are often more highly educated, less likely to have comorbid conditions, and more adherent to treatment protocols than the average patient in the real world. Emerging therapies targeting different Alzheimer’s mechanisms showcase the diversity of approaches now in development. GSK’s presentations of inflammation and immunology research reflect growing recognition that amyloid-targeting monoclonal antibodies like lecanemab and trontinemab may not represent the complete solution to Alzheimer’s disease.
Some patients’ cognitive decline may be driven more by neuroinflammation—overactivation of the brain’s immune system—than by amyloid accumulation. Presentations of these alternative mechanisms help investors and clinicians understand the future landscape where patients may receive combination treatments targeting multiple biological pathways. Anavex Life Sciences’ presentation of ATTENTION-AD data at the J.P. Morgan Healthcare Conference illustrates how emerging biotech companies use investor-focused conferences to gain visibility alongside pharmaceutical giants. Smaller companies often present preliminary or phase II data that larger companies might consider too early-stage for major scientific venues, creating opportunities for investors to discover potential acquisition targets or partnership opportunities before results are widely known.
What Does the Future Hold for Alzheimer’s Treatment Presentations at Investor Conferences?
The schedule of major Alzheimer’s conferences in 2026—with ASIC in May, AAIC in July, and CTAD in November—ensures that investors and researchers will have multiple opportunities throughout the year to assess progress in the field. This cadence reflects the maturation of Alzheimer’s research from a niche area attracting limited investment to a mainstream therapeutic space where new data is continuously emerging. As more treatments move through clinical trials and approach or achieve regulatory approval, these conferences will likely feature increasingly diverse presentations comparing different approaches and mechanisms.
The integration of real-world evidence into investor conference presentations suggests a future where companies must demonstrate not just statistical efficacy in trials but also practical value for patients and healthcare systems. This shift may benefit patients by ensuring that approved treatments actually work in everyday practice, but it also means that clinical trial success alone may no longer be sufficient for market success. Companies will need to invest in post-approval surveillance and long-term outcome tracking to maintain investor confidence and justify premium pricing. The field is moving toward a future where multiple treatment options exist for different patient populations—early-stage Alzheimer’s patients, those with specific genetic profiles, and those with different biological subtypes of the disease—with investor conferences serving as the primary venue for companies to differentiate their approaches and maintain capital support.
Conclusion
Investor conferences have become essential venues for Alzheimer’s treatment companies to present clinical trial data, real-world evidence, and emerging drug candidates to the scientific, clinical, and investment communities. The major conferences—including AAIC, CTAD, AD/PD, and ASIC—draw thousands of researchers and investors from around the world and attract presentations from pharmaceutical giants like Biogen, Roche, and GSK as well as emerging biotech companies. These conferences directly influence which Alzheimer’s treatments are developed, funded, and ultimately brought to patients.
For patients, families, and caregivers, monitoring presentations at these major conferences provides an early window into which treatment approaches are advancing and likely to become available in coming years. The diversity of presentations—from long-term safety data to emerging mechanistic therapies to alternative drug delivery formats—demonstrates that the field has moved beyond a single treatment approach. Staying informed about what companies are presenting at major conferences helps families understand the current state of Alzheimer’s research and make informed decisions about participating in trials or preparing for future treatment options.
You Might Also Like
- Treatment Persistence Data Informs Alzheimer’s Healthcare Planning
- Outcome Measurement Tools Standardize Alzheimer’s Treatment Assessment
- Brain Cell Support Systems Emerge as Alzheimer’s Treatment Targets
For more, see Alzheimer’s Association — medical tests.
